Abstract: Bronchopulmonary dysplasia (BPD) is the most common and important respiratory morbidity of prematurity, affecting thousands of infants worldwide annually. In this presentation, I will highlight the significance of BPD from both individual and societal perspectives, discuss the pulmonary injury sequence, and explore the myths of management, including epidemiologic, ventilatory, and pharmacologic aspects. The latter will include diuretics, bronchodilators, corticosteroids, anti-reflux medications, and others, with a review of the available evidence base. A brief look at agents under current investigation will also be provided.
What will audience learn from your presentation?
- Understand the changing epidemiology of BPD
- Comprehend the multifactorial bases of the pulmonary injury sequence
- Realize that infants with BPD are exposed to a myriad of pharmaceutical agents with dubious efficacy and questionable safety.
Steven M. Donn, MD, FAAP, FAARC is a Professor Emeritus of Pediatrics at the University of Michigan Medical School in Ann Arbor, where he is a member of the Division of Neonatal-Perinatal Medicine at C.S. Mott Children’s Hospital. He is certified by the American Board of Pediatrics and its Sub-board of Neonatal-Perinatal Medicine. Dr. Donn is actively involved in teaching, writing, editing, and clinical research. He is a member of numerous professional societies and is internationally known for his expertise in the management of respiratory failure in newborns. In 2020 he was named a Fellow of the American Association for Respiratory Care for his profound and lasting contribution to the profession of respiratory care. He has authored more than 240 medical journal articles, written or edited 37 books and specialty journals, and contributed 259 book chapters. Dr. Donn’s extracurricular interests include astronomy, international travel, photography, and spectator sports (Go Blue!).